Boehringer Ingelheim licenses Vectron Biosolutions’ expression technology platform
Ingelheim, Germanyand Trondheim, Norway – Boehringer Ingelheim, a research-based, global pharmaceutical company, announced today the licensing of Vectron Biosolutions’ expression technology platform.
This non-exclusive license agreement comes as a result of a successful joint feasibility study between the two companies in which Vectron’s proprietary genetic elements were tested for high-yield, soluble production of a protein of interest to Boehringer Ingelheim in Escherichia coli. This agreement gives Boehringer Ingelheim the right to use Vectron’s technology for both production of biopharmaceutical products from their own in-house pipeline, and as part of the Boehringer Ingelheim BioXcellence™ offerings in contract manufacturing.